Srivastava PK, Mandoiu II, Brennick CA, George MM, and Moussa MM. “Unbiased identification of tumor rejection mediating neoepitopes.” US patent US11920202B2. 2024.

Gillig MA*, Brennick CA*, George MM*,. Balsbaugh JL, Shcheglova TV, Baker BM, Srivastava PK, Karandikar SH. “CD8+ T Cell–Dependent Antitumor Activity In Vivo of a Mass Spectrometry–Identified Neoepitope despite Undetectable CD8+ Immunogenicity In Vitro”. J Immunol 15 December 2023; 211 (12): 1783–1791. *Co-first authors

Brennick CA*, George MM*, Moussa, MM, Hagymasi AT, Seesi SA, Shcheglova TV, Englander RP, Keller GLJ, Balsbaugh JL, Baker BM, Schietinger A, Mandoiu II, Srivastava PK. An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection.” J Clin Invest 131. 2021. *Co-first authors

Brennick CA, George MM, Srivastava PK, Karandikar SH. “Prediction of cancer neoepitopes needs new rules.” Semin Immunol. 2020.

Brennick CA, George MM, Corwin WL, Srivastava PK, Ebrahimi-Nik H. “Neoepitopes as Cancer Immunotherapy Targets: Key Challenges and Opportunities.” Immunotherapy, vol. 9, no. 4, 2017, pp. 361–371.